AMDA Position Statement on Aducanumab

J Am Med Dir Assoc. 2021 Sep;22(9):1777. doi: 10.1016/j.jamda.2021.07.024.

Authors

Lea C Watson¹, Richard Juman²; AMDA Board of Directors

Affiliations

¹ Behavioral Health Council, AMDA, Columbia, MD, USA; Geriatric Psychiatry Consultation and Training, Denver, CO, USA. Electronic address: lea@leawatsonmd.com.
² Behavioral Health Council, AMDA, Columbia, MD, USA; Director of Behavioral Health Policy and Regulations, TeamHealth, Accord, NY, USA.

PMID: 34456010
DOI: 10.1016/j.jamda.2021.07.024

No abstract available

Publication types

Editorial

MeSH terms

Antibodies, Monoclonal, Humanized*
Humans

Substances

Antibodies, Monoclonal, Humanized
aducanumab